Skip to main content
. 2014 Jan 23;25(4):819–826. doi: 10.1681/ASN.2013060575

Table 1.

Baseline characteristics of study population by hemoglobin phenotype

Characteristic HbAA (n=4369) Any Hb Traita (n=633) HbAS (n=513) HbAC (n=120)
Age (yr) 59.8 (14.0) 60.3 (14.1) 60.7 (14.1) 58.5 (14.0)
Sex
 Men 2218 (50.8) 314 (49.6) 261 (50.9) 53 (44.2)
 Women 2151 (49.2) 319 (50.4) 252 (49.1) 67 (55.8)
Weight (kg)b 78.0 (65.0, 94.5) 78.0 (65.2, 92.0) 78.0 (65.4, 91.1) 78.1 (64.4, 99.5)
Hemoglobin (mg/dl) 11.3 (0.7) 11.3 (0.8) 11.2 (0.8) 11.3 (0.7)
ESA dose/treatment (units)b 4364.1 (2237.4, 7903.4) 4737.4 (2566.0, 8645.5) 4701.1 (2611.9, 8489.2) 5449.2 (2550.5, 9832.4)
ESA dose/kg per treatment (units)b 55.5 (27.8, 103.0) 60.5 (33.8, 114.3) 60.0 (33.8, 113.4) 61.0 (34.1, 123.2)
Iron dose (iv)/treatment (mg)b 5.7 (4, 7.6) 5.7 (3.8, 7.6) 5.7 (3.6, 7.6) 6.0 (4.9, 7.9)
Number treatments/mob 12.6 (11.7, 13) 12.7 (12, 13.1) 12.7 (12, 13.1) 12.7 (12, 13.1)
Number treatments totalb 88 (79, 91) 89 (83, 92) 89 (83, 92) 89 (80.5, 92)
Missed treatments (%)b 0 (0, 2.5) 0 (0, 2.2) 0 (0, 2.2) 0 (0, 1.9)
Hospital days/prescribed txsb 0 (0, 0.07) 0 (0, 0.07) 0 (0, 0.06) 0 (0, 0.09)
Dialysis vintage (yr)b 3.4 (1.6, 6.3) 3.3 (1.5, 6.1) 3.3 (1.5, 6.1) 3.7 (1.3, 6.3)
Equilibrated Kt/V 1.46 (0.21) 1.46 (0.18) 1.46 (0.18) 1.45 (0.19)
Albumin (mg/dl) 3.88 (0.35) 3.89 (0.35) 3.89 (0.35) 3.86 (0.36)
Ferritin (ng/ml)b 1001 (712.1, 1260.6) 1002.5 (683.8, 1285.3) 999 (677.6, 1285.5) 1025.9 (764.3, 1249)
Transferrin saturation (%) 34.5 (8.7) 35.0 (9.3) 35.0 (9.3) 34.9 (9.6)
iPTH (pg/ml)b 356.4 (239.4, 565.7) 345.6 (243.5, 528.5) 348.3 (239.3, 540.8) 341.8 (248.7, 516.0)
Vascular access
 AVF 1846 (42.4) 265 (41.9) 211 (41.1) 54 (45.0)
 AVG 1251 (28.7) 191 (30.2) 162 (31.6) 29 (24.2)
 Indwelling catheter 1256 (28.9) 177 (28.0) 140 (27.3) 37 (30.8)
Diabetes 2245 (51.4) 341 (53.9) 270 (52.6) 71 (59.2)

Txs, treatments; iPTH, intact parathyroid hormone.

a

Includes HbAS and HbAC.

b

Median (interquartile range).